Bulletin
Investor Alert

Market Pulse Archives

Oct. 29, 2020, 8:15 a.m. EDT

Moderna's stock is up as it says it is 'actively preparing' for launch of COVID-19 vaccine

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Moderna Inc. (MRNA)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Moderna Inc. /zigman2/quotes/205619834/composite MRNA +7.68% were up 2.9% in premarket trading on Thursday after the company again reminded investors that the Phase 3 clinical trial for its COVID-19 vaccine candidate is fully enrolled as part of its third-quarter earnings announcement. It also said it is "actively preparing for the launch" of its COVID-19 vaccine. Moderna is a preclinical company, meaning it does not yet have an authorized or approved product available on the market. It is developing several mRNA-based vaccines, including one for the coronavirus. The company said its research and development expenses have nearly tripled to $344.5 million in the third quarter of 2020, primarily due to R&D costs for its experimental COVID-19 vaccine, compared with $119.6 million in the same quarter a year ago. Moderna said it plans to conduct two interim analyses for the late-stage trial of the vaccine. Moderna's stock has gained 236.1% so far this year, while the S&P 500 /zigman2/quotes/210599714/realtime SPX +1.49% is up 1.2%.

/zigman2/quotes/205619834/composite
US : U.S.: Nasdaq
$ 161.38
+11.51 +7.68%
Volume: 6.51M
May 14, 2021 4:00p
P/E Ratio
128.69
Dividend Yield
N/A
Market Cap
$64.80 billion
Rev. per Employee
$617,996
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,173.85
+61.35 +1.49%
Volume: 1.91B
May 14, 2021 5:02p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.